INTRODUCTION

The vascular system is essential for providing oxygen and nutrients, removing metabolic waste products, and furnishing efficient access of leukocytes to tissues throughout larger animals.

Angiogenesis, the sprouting of new capillaries, is required for the development of the vascular system and, consequently, the growth of vertebrates.1 Vascular endothelial growth factor (VEGF) is a pivotal regulator of angiogenesis and is suggested to play an important role in tumor growth and dissemination.2,3 Besides being a tumor growth-promoting factor, VEGF is also characterized as an inflammatory molecule.4 It is synthesized by a variety of inflammatory cells including endothelial cells, megakaryocytes, granulocytes,5 activated lymphocytes,7 and macrophages8 and may be released from these cells following activation.9 Thereby VEGF may contribute to local hyperpermeability of traumatized or inflamed tissue as well as induce revascularization of the inflamed area.

ABSTRACT

Objective: Anesthesia and surgical intervention, leads to the development of systemic inflammatory response. The severity of the inflammatory response depends on the pharmacological effects of anesthetic agents and duration of anesthesia. Objective of the study was to investigate the effect of nitrous oxide on VEGF and VEGFR1 levels in patients undergoing surgery.

Methods: Forty-four patients undergoing elective urological surgery were included in the study. Anesthesia maintenance was provided with 1-2 MAC sevoflurane, O₂ 50%, N₂O 50% in 4L/m transporter gase for group 1 (n=22) and 1-2 MAC sevoflurane, O₂ 50%, air 50% in 4L/m transporter gase for group 2 (n=22) Venous blood samples for the measurement of VEGF and VEGFR1 were taken before the induction of anesthesia, 60 minutes of anesthesia induction, at the end of anesthesia and 24 hours after operation. In statistical analysis Bonferroni test and analysis of variance at the repeated measures were used

Results: In the postoperative period serum VEGF levels had decreased significantly in both group whereas VEGFR1 did not show a significant change.

Conclusions: Nitrous oxide showed significant effect on angiogenic parameters. Further detailed studies are required to evaluate the effect of nitrous oxide.

KEY WORDS: Nitrous oxide, VEGF, VEGFR1, Urological Surgery.
Several receptors for VEGF have been identified. Of these the soluble form of VEGFR1 (sVEGFR1) is presumed to antagonize the effects of VEGF by a direct competitive binding of VEGF.

Nitrous oxide (N\textsubscript{2}O; laughing gas) has been widely used in clinical practice for decades because its effective analgesic properties are achieved at concentrations below those required for general anesthesia. Nevertheless, several adverse effects, including megaloblastic anemia, homocysteinemia and its possible risk for atherosclerosis, thrombosis, cognitive dysfunction, neurotoxicity, possible teratogenicity, increased intracranial pressure and cerebral blood flow, expansion of air spaces and hypoxia, post-operative nausea and vomiting, and possible immunosuppression are known.

Surgical trauma is followed by inflammatory and wound healing processes, with local release of various growth factors including VEGF. In animal models, surgery, trauma and inflammation have been shown to facilitate angiogenesis, tumour growth and metastasis, the effect being both local and systemic. The stress response to surgery is a major neuroendocrine and cytokine response to surgical trauma, characterized by increases in catecholamine and steroid hormones, with predictable metabolic consequences, including hyperglycemia and negative nitrogen balance. It is possible that cytokines increased by the surgical stress response may be linked with some of the angiogenic factors associated with elective urological surgery.

The aim of the present study was to investigate the influence of nitrous oxide on VEGF and VEGFR1 in order to detect any effect that this agent might have on an inflammatory response.

METHODS

This study was approved by Ethical Committee at Karaelmas University Application and Research Hospital CM, dated January 15\textsuperscript{th}, 2009. Forty four Society of Anesthesia (ASA) risk scores I-III adult patients who were between 18 and 65 years and were to undergo an elective urological surgical initiative that would last 1 to 4 hours in the main operation room at Karaelmas University Application and Research Hospital were included. The study was conducted between January 2009 and January 2010. Patients with chronic metabolic diseases, liver failures and acute anemia were not included.

All the patients were applied the standard IM midazolam (0.07 mg/kg) premedication one hour before the surgery. Blood samples were taken from the patients prior to anesthesia in order to determine their VEGF, VEGFR1 levels. Before induction, all the patients were applied 5-7 ml/kg Ringer Laktat fluid replacement. All patients were preoxygenated with 10 L/dk 100% of oxygen for one minute. Anesthetic induction was done with 2.4 mg/kg of propofol and 1 µg/kg of fentanyl. Intubation was done three minutes after 0.6 mg/kg of rocuronium was given as a muscle relaxant agent. Following the intubation, a high current of 6 L/dk was applied for 5 minutes.

Maintenance of anesthesia was done with 1-2 MAC sevoflurane in group 1 (n=22), keeping O\textsubscript{2} at 50% and N\textsubscript{2}O at 50% and with 1-2 MAC sevoflurane in group 2 (n=22) under 4 L/dk carrier gas, keeping O\textsubscript{2} at 50% and air at 50%. Maintenance analgesia need was met in group 2 with 1 mcg/kg/saat fentanyl infusion. Ventilation tidal volume (TV) was kept at 6-8 ml/kg, I:E ratio at 1:2 and respiratory frequency was maintained in a way to keep ETCO\textsubscript{2} at 35-40 mmHg, which makes normocapnia possible. FiO\textsubscript{2} value was preserved between 30 and 35%. Anesthetics were stopped and patient was ventilated with 100% of O\textsubscript{2} when the last skin suture was begun before the operation ended. Muscle relaxant was antagonised with 0.05 mg / kg of neostigmin and 0.01 mg/kg of atropine. The patient was respirated by hand after the antagonists were applied and spontaneous respiration was controlled every ten seconds. In order to determine the levels of VEGF and VEGFR1, blood samples were taken from patients.

After vascular access was obtained, blood samples were taken from all the patients before anesthesia (Pre-operative 0th min), at the 60th min of anesthesia (Intra-operative 60th min), after anesthetic agents were stopped (Post-operative 0th min) and at Post-operative 24 hr. After the blood samples were congealed, they were centrifuged at 3500 rpm for five minutes. The serums separated after centrifuges were kept to be analysed at -80C. VEGF measurement: VEGF levels were assayed by an enzyme-linked immunosorbent assay (ELISA) kit (Catalog No: KHG0112: 1 plate, Camarillo, USA). Detection limit of the assay is <5 pg/ml. VEGFR1 measurement: VEGFR1 levels were assayed by an enzyme-linked immunosorbent assay (ELISA) kit (Catalog No: BMS268/2: 1 plate, Vienna, Austria). Detection limit of the assay is 6 ng/ml. Statistical analysis: Statistical evaluation was done using the SPSS 18.0 program. Descriptive statistics were expressed as mean ± standard deviation for
numeric data and as number and percentage for categorical data. Compatibility of the measured variables with normal distribution was examined with the Kolmogorov-Smirnov test. Significance test of the difference between two means was used for the differences of measured variables between the groups. Differences of categorical variables between the groups were evaluated with chi-square test. Changes in measured variables in time for the repetitive measurements were examined with single direction variance analysis.

Paired comparisons were done with Bonferroni test when analysis yielded any differences. Results were evaluated in 95% confidence interval and statistical significance was taken as p<0.05.

RESULTS

The measurement values of VEGF and VEGFR1 belonging to the group of nitrous oxide-administered patients at preop, intraop 60th minute, postop 0th minute and postop 24th hours are given in Table-I.

The change in VEGF depending on time in the nitrous oxide-administered patient group was found to be significant (p<0.001). VEGF levels in preop. 0th min is statistically higher than other times. There was no significant difference between the levels of VEGF at other times.

No significant difference between times in terms of VEGFR1 was found in the group of patients who receive nitrous oxide (p=0.159).

Table-I: The significance of change in parameters depending on time in the nitrous oxide-administered patient group*

| Parameter         | Preop. (0th minute) | Intraop. (60th minute) | Postop. (0th minute) | Postop. (24th hours) | P   |
|-------------------|---------------------|------------------------|----------------------|----------------------|-----|
| VEGF (pg/ml)      | 364.06±153.66       | 262.88±136.91          | 237.72±136.91        | 233.64±120.01        | <0.001 |
|                   | (87.7-750.0)        | (57.7-750.0)           | (63.6-625.3)         | (38.7-518.1)         |     |
| Soluble VEGFR1(ng/ml) | 0.18±0.06          | 0.22±0.05              | 0.19±0.06            | 0.27±0.26            | 0.159 |
|                   | (0.06-0.338)        | (0.112-0.298)          | (0.084-0.379)        | (0.003-1.383)        |     |

* The results were indicated as Mean±SD N=22

The change in VEGF depending on time in the group of patients who did not receive nitrous oxide was found to be significant (p=0.013). The difference between the levels of VEGF at Preop 0th minute and those at all the other times was found to be significant. There was no significant difference between the levels of VEGF at other times.

No significant difference between times in terms of VEGFR1 was found in the group of patients who did not receive nitrous oxide (p=0.334).

DISCUSSION

Angiogenesis, or the formation of new blood vessels from pre-existing ones plays a pivotal role during embrional development and later, in adult life, in a variety of physiological and pathological conditions, such as malignancy and chronic inflammation. Diseased or injured cells in response to genetic alterations, hypoxia, hypoglycemia, mechanical stress, and/or inflammatory proteins, release pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) into the surrounding tissue. VEGF is the major endogenous regulator of endothelial cell proliferation, migration, and differentiation.

Svendsen et al (2005) investigated that the effect of major and minor surgery on variations in sVEGF and sVEGFR1 concentrations in vivo and on bacterial antigen induced release of sVEGF and sVEGFR1 from whole blood in vitro. They suggested that plasma sVEGF and sVEGFR1 concentrations did not change during surgery and in vitro bacterial stimulation led to increased release of sVEGF, which was not compensated for by an equivalent increase in sVEGFR1.

Table-II: Significance of the change in parameters in the group of patients who were not administered nitrous oxide depending on time*

| Parameter         | Preop. (0th minute) | Intraop. (60th minute) | Postop. (0th minute) | Postop. (24th hours) | P   |
|-------------------|---------------------|------------------------|----------------------|----------------------|-----|
| VEGF (pg/ml)      | 95.95±45.97         | 86.30±47.10            | 82.44±47.22          | 82.75±35.21          | 0.013 |
|                   | (40.5-209.7)        | (25.7-192.7)           | (22.2-207.6)         | (33.4-159.4)         |     |
| Soluble VEGFR1(ng/ml) | 0.22±0.018         | 0.20±0.08              | 0.22±0.09            | 0.21±0.009           | 0.334 |
|                   | (0.1-1.0)           | (0.1-0.4)              | (0.1-0.4)            | (0.1-0.5)            |     |

* The results were indicated as Mean±SD N=22
Svendsen et al (2005) also evaluated perioperative plasma concentrations of soluble VEGF (sVEGF) and soluble VEGFR1 (sVEGFR1) in patients undergoing elective colectomy. They found that the major surgical trauma led to significant intra- and postoperative changes in sVEGF and sVEGFR1. The high preoperative levels were significantly decreased 30 days after surgery. The intra- and postoperative changes of both molecule levels were similar in patients undergoing laparoscopically assisted and open colectomy.  

An insignificant decrease was observed on the post-operative day one in the study in which Futami R et al investigated serum VEGF levels following a major surgical damage. However, there was an increase in the serum VEGF levels after the day one. It was reported that this increase peaked on the postop day 14. Researchers suggested that the postoperative VEGF increase might be the angiogenetic response to tissue repair. Compared with preop levels, VEGF levels were found to be low at postop 4 and 24 hours in the 30 patients who had mastectomy operation under general anasthesia using nitrous oxide but no statistically significant difference was found. A significant decrease was seen in VEGF levels in patients with oesophageus cancer on day one following surgical trauma. VEGF levels started to increase on day three and receded to preop levels on day five. VEGF and soluble VEGFR1 levels were examined in a study in which 61 patients of abdominal surgery who were given general anaesthesia without giving them nitrous oxide. A decrease was detected in the postop day 4 and 24 hours in the 30 patients who had mastectomy operation under general anasthesia using nitrous oxide but no statistically significant difference was found. A significant decrease was seen in VEGF levels in patients with oesophageus cancer on day one following surgical trauma. VEGF levels started to increase on day three and receded to preop levels on day five.

In another study which investigated the effect of open and laparoscopic colectomy on VEGF and soluble VEGFR1, a significant fluctuation in VEGF and soluble VEGFR1 levels was detected depending on time. While serum VEGF levels were at their lowest at intraop hour 1, there was an increase after the operation and VEGF levels receded to preop concentrations on the postop day 30. When serum soluble VEGFR1 levels were compared with preop levels, a decrease was seen at the intraop hours 1, 2 and 6. VEGFR1 levels dropped below preop levels on the day 30. In our study, VEGF levels decreased in both groups during the surgery. However, the fact that Intra-operative 60th min according to Pre-operative 0th min VEGF levels decreased (28%) more in the group who were given nitrous oxide than the group (11%) who were not given nitrous oxide suggests that the decrease occurred due to nitrous oxide. The fact that there was not a significant change in serum soluble VEGFR1 levels in both groups shows that soluble VEGFR1 did not contribute to the decrease in VEGF levels. These results suggest that the decrease in VEGF levels were due to dilutional effect arising from stress response.

Conflicts of Interest: There are no conflicts of interest. No company or institution might benefit from the publication.

REFERENCES

1. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic Agent. J Biol Chem. 1996;271(2):603-606.
2. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (Experientia Supplementum). 1997;79:233-269.
3. Ellis LM. A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am Surg. 2003;69(1):3-10.
4. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol. 2000;26(7):657-662.
5. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77(6):956-964.
6. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood. 1997;90(10):4153-4161.
7. Freeman MR, Schnee FX, Gagnon ML, Corless C, Soker S, Niknejad K, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55(18):4140-4145.
8. Sunderrkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol. 1994;55(3):410-422.
9. Nielsen HJ, Werther K, Mynster T, Svendsen MN, Rosendahl S, Elley T, et al. Bacteria-induced release of white cell- and platelet derived vascular endothelia growth factor in vitro. Vox Sang. 2001;80(3):170-178.
10. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci. 1999;4:141-152.
11. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Anqiology. 2001;4(2):143-154.
12. Mennerick S, Jevtovic-Todorovic V, Todorovic SM, Shen W, Olny JW, Zorumski CF. Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci. 1998;18(23):9716-9726.
13. Lehmberg J, Waldner M, Baethmann A, Uhl E. Inflammatory response to nitrous oxide in the central nervous system. Brain Res. 2008;1246:88-95.
14. Nissen NN, Polverini PJ, Koch AE, Vinin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152(6):1445-1452.
15. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Invest Dermatol Symp Proc. 2000;5(1):40-46.

16. Murthy SM, Goldschmidt RA, Rao LN, Ammirati M, Buchmann T, Scanlon EF. The influence of surgical trauma on experimental metastasis. Cancer. 1989;64(10):2035-2044.

17. Lee JY, Murphy SM, Scanlon EF. Effect of trauma on implantation of metastatic tumor in bone in mice. J Surg Oncol. 1994;56(3):178-184.

18. O’Riain SC, Buggy DJ, Kerin MJ, Watson RW, Moriarty DC. Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2. Anesth Analg Jan. 2005;100(1):244-249.

19. Yildirim NC, Yurekli M. Adrenomedullin administration alters vascular endothelial growth factor levels in rats in cold stress. Asian Biomedicine. 2010;4(6):955-958.

20. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.

21. Crowther M, Brown NJ, Bishop ET, Lewis CE. Micro environmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 2001;70(4):478-490.

22. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22.

23. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-5443.

24. Svendsen MN, Lykke J, Werther K, Bisgaard T, Christensen IJ, Nielsen HJ. Bacterial antigen induced release of soluble vascular endothelial growth factor (VEGF) and VEGFR1 before and after surgery. Scand J Clin Lab Invest. 2005;65(3):237-247.

25. Svendsen MN, Werther K, Christensen IJ, Basse L, Nielsen HJ. Influence of open versus laparoscopically assisted colectomy on soluble vascular endothelial growth factor (sVEGF) and its soluble receptor 1 (sVEGFR1). Inflamm Res. 2005;54(11):458-463.

26. Futami R, Miyashita M, Nomura T, Makino H, Matsutani T, Sasajima K, Tajiri T. Increased serum vascular endothelial growth factor following major surgical injury. J Nippon Med Sch. 2007;74(3):223-229.

27. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN. Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg. 2001;88(8):1105-1109.

Authors Contribution:

YH conceived, designed and did statistical analysis and editing of manuscript. MC was involved in clinical management of patients. SH did data collection and manuscript writing. NCY, SA & AGM contributed in manuscript writing. NAM & IOT did review and final approval of manuscript.